Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Peripheral arterial occlusive disorders

14

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

13

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Carnitine O-acetyltransferase

13

Carnitine O-palmitoyltransferase 1, liver isoform

13

Carnitine O-palmitoyltransferase 1, muscle isoform

13

Carnitine O-palmitoyltransferase 2, mitochondrial

13

Mitochondrial carnitine/acylcarnitine carrier protein

13

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

13

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1985

13

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

14

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

13

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sigma-Tau

13

NicOx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

14

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

14

PUBCHEM

14

CAS

13

EPA CompTox

9

SMS_ID

9

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Amino acids and derivatives

1

Other psychostimulants and nootropics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

12

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

LEVOCARNITINE

0G389FZZ9M

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

NCX-4016

EH04H13L6B

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Cyclooxygenase-1

platelet aggregation

thromboxane A2 signaling pathway

Conditions:

Peripheral arterial occlusive disorders

Type 2 diabetes mellitus

Colorectal cancer

NCX-4016, a nitric oxide non-steroidal anti-inflammatory drug (NO-NSAID) which can inhibit cyclooxygenase as well as release nitric oxide, is under development by NicOx as a potential treatment for thrombosis, inflammation and rheumatoid arthritis. N...

CX-4016 possesses a broad spectrum of antithrombotic and antiinflammatory activities. NCX-4016 has been shown to inhibit platelet activation in vitro more effectively than aspirin, to inhibit smooth muscle cell proliferation, to exert an endothelial cell protective activity and to suppress the function of several inflammatory cells potentially involved in atherothrombosis. In animal models, NCX-4016 protected from platelet thromboembolism, prevented restenosis in atherosclerosis-prone animals, protected the heart from ischemia/reperfusion injury, and induced neoangiogenesis in critically ischemic limbs. Moreover, it displayed little or no gastric toxicity and appeared to protect stomach from noxious stimuli, including aspirin. NCX-4016 has been evaluated in healthy volunteers and found to inhibit platelet cyclo-oxygenase-1 (COX-1) similarly to or slightly less than aspirin, to raise the circulating levels of NO-degradation products, and to have little or no gastric toxicity in short term studies. NCX-4016 was in Phase II clinical trials for the treatment of vascular disorders such as peripheral vascular disease and other cardiovascular diseases including thrombosis, complications of endothelium-related diseases such as diabetes and other. But this research was discontinued.

LEVOCARNITINE FUMARATE

8Q37GK439O

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

ACETYL-L-CARNITINE ARGINATE DIHYDROCHLORIDE

DDL9STT4CE

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

GLYCINE PROPIONYL-L-CARNITINE HYDROCHLORIDE

LY38SJU4DG

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

GLYCINE PROPIONYL-L-CARNITINE

8KVN59D5FL

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

ACETYL-L-CARNITINE ARGINATE

PIY2W03CO6

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

LEVOCARNITINE MONOTARTRATE

4OCB0F120X

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

LEVOCARNITINE PROPIONATE

0HU2UI27HF

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

LEVOCARNITINE PROPIONATE HYDROCHLORIDE

12FW2YBF04

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1